CVSA Covista Inc.
Covista Inc., together with its subsidiaries, provides healthcare education in the United States, Barbados, St. Kitts, and St. Maarten. It operates in three segments: Chamberlain, Walden, and Medical and Veterinary. The company provides degree programs, including bachelor's, master's, and doctoral degrees; and online certificate programs for nursing, health professions, medical, and veterinary postsecondary education, counseling, business, information technology, psychology, public health, social work and human services, public administration and public policy, and criminal justice. It also operates Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. The company was formerly known as Adtalem Global Education Inc. and changed its name to Covista Inc. in February 2026. Covista Inc. was incorporated in 1987 and is headquartered in Chicago, Illinois.…
Industry Peers
Education & Training ServicesKey Statistics
About Covista (NYSE: CVSA)
›
Covista (NYSE: CVSA) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Education & Training Services industry, part of the Consumer Defensive sector, and reports about 4,736 employees.
The shares were at 115.51 USD on 19 November 2026, up 19.7% over 52 weeks. Its 52-week range is 86.97 USD to 142.13 USD: the price is 18.7% below the high and 32.8% above the low.
At a market capitalisation of 3.84B USD, it trades at 14.6 times trailing earnings and 11.4 times forward earnings. The median trailing P/E of its 17 largest Education & Training Services peers is 15.9, so CVSA is valued in line with them.
Covista reports return on equity of 17.4%, an operating margin of 20.1% and revenue up 10.7% year over year.
Its debt exceeds its cash by 531.37M USD, a debt-to-equity ratio of 0.63. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 4 analysts cover the stock; their mean price target of 159.00 USD is 37.7% above the current price. The next earnings report is expected on 28 January 2027.